AusPAR: Elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (as fumarate)

Australian Public Assessment Report

AusPAR

AusPAR: Elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (as fumarate) [PDF, 968.59 KB]

AusPAR: Elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (as fumarate) [Word, 1.65 MB]

Attachment: Product Information: Elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (as fumarate) [PDF, 634.66 KB]

Attachment: Product Information: Elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (as fumarate) [Word, 191.71 KB]

Attachment: Extract from Clinical Evaluation: Elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (as fumarate) [PDF, 1.08 MB]

Attachment: Extract from Clinical Evaluation: Elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (as fumarate) [Word, 730.75 KB]

Device/Product Name

Genvoya

Active ingredients

Elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (as fumarate)

AusPAR Date

18 October 2018

Published

21 November 2018

Submission Number

PM-2016-04632-1-2

Submission Type

Extension of indications

Decision

Approved